Auscann Group Holdings Ltd
ASX:AC8
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| AU |
|
Auscann Group Holdings Ltd
ASX:AC8
|
17.6m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
285.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
238.6B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD |
Loading...
|
Market Distribution
| Min | -6 907 100% |
| 30th Percentile | 21.6% |
| Median | 38.3% |
| 70th Percentile | 58.2% |
| Max | 2 095.9% |
Other Profitability Ratios
Auscann Group Holdings Ltd
Glance View
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Auscann Group Holdings Ltd is 100.6%, which is above its 3-year median of 100.3%.
Over the last 3 years, Auscann Group Holdings Ltd’s Gross Margin has increased from 84.2% to 100.6%. During this period, it reached a low of 84.2% on Dec 31, 2020 and a high of 100.6% on Jan 1, 2024.
